Published in J Clin Oncol on April 20, 2008
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol (2015) 1.71
Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol (2009) 1.67
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res (2011) 1.46
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol (2014) 1.22
Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol (2014) 1.21
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer (2009) 1.15
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer (2010) 1.10
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res (2009) 1.10
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2012) 1.10
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol (2010) 1.10
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A (2012) 1.09
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer (2010) 1.07
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03
Triple-negative breast cancers: an updated review on treatment options. Curr Oncol (2011) 1.03
Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene (2012) 1.00
Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist (2010) 1.00
Emerging strategies for treating brain metastases from breast cancer. Cancer Cell (2015) 1.00
Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol (2012) 0.99
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer (2011) 0.96
Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis (2015) 0.94
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol (2012) 0.94
Targeted therapies in brain metastases. Curr Treat Options Neurol (2014) 0.93
Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist (2013) 0.93
Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol (2013) 0.93
Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis (2011) 0.92
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst (2015) 0.92
Targeted therapy in HER2-positive breast cancer. Biomed Rep (2013) 0.91
Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology (2007) 0.91
Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med (2013) 0.90
Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience (2013) 0.89
A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer (2011) 0.89
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol (2015) 0.89
Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res (2015) 0.88
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer (2012) 0.88
Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget (2015) 0.87
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer (2012) 0.87
Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol (2010) 0.87
Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer (2009) 0.87
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res (2014) 0.87
Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles. ScientificWorldJournal (2012) 0.85
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus (2014) 0.85
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag Res (2010) 0.85
Treatment of Breast Cancer Brain Metastases. Curr Breast Cancer Rep (2011) 0.85
Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) (2012) 0.83
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist (2012) 0.83
Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. Clin Exp Metastasis (2012) 0.82
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro Oncol (2014) 0.82
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014. Breast Care (Basel) (2014) 0.82
Lapatinib-induced hepatitis: a case report. World J Gastroenterol (2011) 0.81
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol (2011) 0.81
Treatment of vestibular schwannoma cells with ErbB inhibitors. Otol Neurotol (2012) 0.81
Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press) (2010) 0.81
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J (2010) 0.81
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol (2016) 0.81
Targeted Therapies for Brain Metastases from Breast Cancer. Int J Mol Sci (2016) 0.80
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer (2010) 0.80
Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health (2010) 0.80
Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease. Clin Breast Cancer (2012) 0.80
The molecular genomics of metastatic brain tumours. OA Mol Oncol (2013) 0.80
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J (2016) 0.79
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press) (2011) 0.79
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol (2010) 0.79
Molecular aspects of breast cancer metastasis to the brain. Genet Res Int (2011) 0.79
The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Contemp Oncol (Pozn) (2013) 0.79
Assessment of prognostic scores in brain metastases from breast cancer. Neuro Oncol (2013) 0.79
Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat (2014) 0.79
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat (2014) 0.78
New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.78
Brain metastasis and treatment. F1000Prime Rep (2014) 0.77
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. J Cancer Ther (2012) 0.77
Are volumetric changes of brain metastases the best evaluation of efficacy? J Clin Oncol (2008) 0.77
A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier. Cancer Prev Res (Phila) (2014) 0.77
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget (2015) 0.76
Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549). J Pharm Drug Deliv Res (2015) 0.76
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. Int J Clin Oncol (2015) 0.75
Targeted treatment of advanced and metastaticbreast cancer with lapatinib. Onco Targets Ther (2008) 0.75
Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation. Case Rep Oncol Med (2013) 0.75
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Invest New Drugs (2013) 0.75
Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). Drug Des Devel Ther (2016) 0.75
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). Chem Biol Drug Des (2016) 0.75
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. J Cancer Res Ther Oncol (2014) 0.75
Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine. Case Rep Oncol (2014) 0.75
Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells. Oncotarget (2016) 0.75
Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. J Cancer Ther (2015) 0.75
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clin Breast Cancer (2016) 0.75
Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol (2012) 0.75
Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials. J Med Imaging (Bellingham) (2017) 0.75
Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review. Breast Care (Basel) (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 4.47
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 3.87
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
Trastuzumab in CSF. J Clin Oncol (2000) 2.35
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol (2004) 1.79
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer (2004) 1.57
Confidence limits for probability of response in multistage phase II clinical trials. Biometrics (1985) 1.34
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys (2004) 1.21
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer (2006) 1.20
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol (2006) 1.17
Response of brain metastases from breast cancer to systemic chemotherapy. Cancer (1992) 1.10
Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol (1988) 0.93
Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer (1995) 0.91
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br J Cancer (2003) 0.90
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood (2003) 20.10
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2014) 4.61
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 4.47
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Initialization, noise, singularities, and scale in height ridge traversal for tubular object centerline extraction. IEEE Trans Med Imaging (2002) 4.19
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Informing clinical trial participants about study results. JAMA (2002) 3.76
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer (2008) 3.43
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol (2006) 3.33
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol (2008) 3.04
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Animal models for medical countermeasures to radiation exposure. Radiat Res (2010) 2.83
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene (2003) 2.82
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol (2010) 2.80
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
A brain tumor segmentation framework based on outlier detection. Med Image Anal (2004) 2.62
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) (2012) 2.50
Language-association cortex asymmetry in autism and specific language impairment. Ann Neurol (2004) 2.49
High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. Am J Gastroenterol (2010) 2.47
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Automatic brain tumor segmentation by subject specific modification of atlas priors. Acad Radiol (2003) 2.44
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Structure and mechanism of an amino acid antiporter. Science (2009) 2.40
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37